The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.
Oncolytic viruses selectively lyse tumor cells, making these agents a promising treatment modality for glioma. Accumulating data suggest that the immune system plays an important role in the anti-glioma activity of oncolytic viruses. In an immune competent glioma model, the therapeutic effect of the oncolytic adenovirus Delta24-RGD was found to depend primarily on antitumor immune responses.
Department of Neurosurgery; Brain Tumor Center ; ErasmusMC ; Rotterdam, The Netherlands.
Anne
A
Kleijn
Department of Neurosurgery; Brain Tumor Center ; ErasmusMC ; Rotterdam, The Netherlands.
Jenneke
J
Kloezeman
Laboratory of Experimental Tumor Immunology; Dept of Medical Oncology ; ErasmusMC ; Rotterdam, The Netherlands.
Elike
E
Treffers-Westerlaken
Brain Tumor Research Center; Molecular Neurosurgery Laboratory ; Department of Neurosurgery; Massachusetts General Hospital ; Boston, MA USA.
Giulia
G
Fulci
Department of Neurosurgery; Brain Tumor Center ; ErasmusMC ; Rotterdam, The Netherlands.
Sieger
S
Leenstra
Department of Neurosurgery; Brain Tumor Center ; ErasmusMC ; Rotterdam, The Netherlands.
Clemens
C
Dirven
Laboratory of Experimental Tumor Immunology; Dept of Medical Oncology ; ErasmusMC ; Rotterdam, The Netherlands.
Reno
R
Debets
Department of Neurosurgery; Brain Tumor Center ; ErasmusMC ; Rotterdam, The Netherlands.
Martine
M
Lamfers
 adenovirus; antitumor immunity; glioma; immune response; virotherapy